The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Ann Rheum Dis. 2016 Jun;75(6):1092-8. doi: 10.1136/annrheumdis-2014-207164. Epub 2015 May 18.

Abstract

Objective: To describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis (JIA) and to identify clinical features associated with an increased risk of flare.

Methods: We studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan-Meier methods, and associated features were identified using Cox regression.

Results: 1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare.

Conclusions: In this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.

Keywords: Disease Activity; Epidemiology; Juvenile Idiopathic Arthritis.

MeSH terms

  • Antibodies, Antinuclear / blood
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Juvenile / blood
  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / pathology*
  • Biological Factors / therapeutic use
  • Canada
  • Child
  • Disease Progression*
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Outcome Assessment, Health Care
  • Proportional Hazards Models
  • Prospective Studies
  • Recurrence
  • Rheumatoid Factor / blood
  • Risk Factors
  • Severity of Illness Index
  • Time Factors

Substances

  • Antibodies, Antinuclear
  • Antirheumatic Agents
  • Biological Factors
  • Rheumatoid Factor

Grants and funding